Table 2 Selected effectiveness parameters after three months, six months, 12 months, 18 months and 24 months
| Â | Month 0 | Month 3 | Month 6 | Month 12 | Month 18 | Month 24 |
|---|---|---|---|---|---|---|
Physician global assessment; median (IQR) | ||||||
 persistent oligoJIA | 40 (20; 63) | 7 (2; 17) | 3 (1; 13) | 3(1;13.5) | 3 (0; 13) | 2 (0; 8) |
 extended oligoJIA | 45 (25; 65) | 12 (4; 23) | 8.5(2,5; 20,5) | 3(1; 13.5) | 3 (0; 13) | 3 (0; 11) |
 RF negative PA | 54.5 (34; 79) | 15 (5; 29) | 9 (3; 20) | 5 (1; 16) | 3 (0; 10) | 3 (0; 7) |
parents/patient global assessment; median (IQR) | ||||||
 persistent oligoJIA | 35 (11; 55) | 6 (2; 19) | 4 (1; 13) | 3 (0, 11) | 2 (0, 9) | 2 (0; 10) |
 extended oligoJIA | 36 (15; 55) | 12(2; 29) | 7 (2; 18) | 5 (1,18) | 3 (0; 17) | 2 (0, 16) |
 RF negative PA | 44 (22; 63) | 14 (4; 31) | 8 (2; 22) | 6 (1; 19) | 3 (0; 19) | 3 (0; 11) |
CRP > 5; n (%) | ||||||
 persistent oligoJIA | 117 (33.7) | 27 (13.6) | 20 (11.1) | 9 (5.4) | 10 (6.6) | 10 (8.1) |
 extended oligoJIA | 91 (45) | 26 (20.6) | 21 ((16.7) | 17 (14.5) | 12 (12.1) | 11 (11.6) |
 RF negative PA | 217 (48.5) | 53 (18.3) | 53 (18.7) | 44 (17.5) | 22 (10.5) | 18 (10.2) |